Obesity and colon cancer

Share This Post

According to a recent study  published in JAMA Oncology, obesity is  associated with an increased risk of early-onset colorectal cancer (CRC) in women.

A medical doctor from Boston Massachusetts General Hospital conducted a study to determine the occurrence of colorectal cancer in 85,256 women without cancer and inflammatory bowel disease based on data from 25-42 -year-old women .

The researchers discovered 114 cases of early-onset CRC (median age at diagnosis, 45 years) during the study period . For overweight women (body mass index [BMI] , 25-29.9 kg / m² ) and obese women (BMI, ≥30 kg / m²) with standard weight ( BMI is 18.5-22.9 kg / m² ) compared with women, CRC increased risk . This finding can be attributed to BMI at 18 years of age and weight gain after 18 years of age. For every 5 units of BMI increase , the RR (relative risk) of colorectal cancer increases by 1.2 . Comparative 18 years old BMI was 18.5-20.9 kg m² / female, BMI is 21 – 22.9 kg / m² women, early onset CRC of RRIs 1.32 , BMI is ≥23kg female RR was 1.63 . Similarly, compared with women who gained less than 5 kg or lost weight, women had an increase of 20-39.9 kg in early-onset CRC with an RR of 1.65 , women with an increase of ≥40 kg and an RR of 2.15.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS
Cancer

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer
Bladder cancer

Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer

“Nogapendekin Alfa Inbakicept-PMLN, a novel immunotherapy, shows promise in treating bladder cancer when combined with BCG therapy. This innovative approach targets specific cancer markers while leveraging the immune system’s response, enhancing the efficacy of traditional treatments like BCG. Clinical trials reveal encouraging results, indicating improved patient outcomes and potential advancements in bladder cancer management. The synergy between Nogapendekin Alfa Inbakicept-PMLN and BCG heralds a new era in bladder cancer treatment.”

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy